Rexlemestrocel-l to be highlighted at maxim's panel on late-stage advancements in heart failure therapeutics and management

New york, july 11, 2022 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-l, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (chf) with reduced ejection fraction (hfref), will be highlighted in a panel discussion titled “late-stage advancements in heart failure therapeutics and management”, presented by maxim group llc and hosted by m-vest, on thursday, july 14th, 2022 at 10:00 a.m. et. the link to the webcast is available here.
MESO Ratings Summary
MESO Quant Ranking